NEW YORK — Shares of biotechnology company Human Genome Sciences Inc. fell Tuesday after the company’s first-quarter results disappointed investors.

Shares fell 50 cents, or 7.5 percent, to $6.13. The stock has traded between $4.74 and $11.95 over the last 52 weeks.